Cytokinetics EVP Fady Malik Sells Stock Amid Myqorzo Launch Momentum
Cytokinetics Inc. (NASDAQ: CYTK) Executive Vice President of Research & Development Fady Malik executed a series of transactions on July 21, 2026, selling 3,500 shares of common stock while simultaneously exercising non-qualified stock options to acquire an equal number of shares. The sale was reported at $80.59 per share, totaling $282,065, while …